EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to ...

Rami Owera, MD, medical oncologist and hematologist with Woodlands Specialty Physicians, a division of Florida Cancer ...

Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found tolerable and showed signs of efficacy in a real-world cohort. Delandistrogene ...

Researchers share their experience with sotatercept in 91 patients with pulmonary arterial hypertension, the first report on outcomes outside clinical studies.

Ontada will present a real-world research study at the ASCO Annual Meeting examining GLP-1 receptor agonist utilization and overall survival outcomes.

Brentuximab vedotin with CHP is effective and safe for first-line PTCL treatment, achieving an 80% overall response rate. Median progression-free survival was 39.7 months, with a 1-year overall ...

Sensitive skin affects up to 70% of people globally – a figure that has risen by 68% over the past two decades – yet it remains widely overlooked and under-studied. 2,3 As more people live fast-paced ...

LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline TP53 Mutations Among 187 patients identified (median follow-up, 22.4 ...

Erleada significantly reduces the risk of death by 51% in mCSPC patients compared to Nubeqa, without chemotherapy, over 24 months. The study used inverse probability of treatment weighting to ensure ...

Lutathera showed antitumor activity in metastatic BP-NETs, with partial responses in 17% of patients and stable disease in 30%. The study reported a median progression-free survival of 10.8 months and ...